Masimo Hosts 2025 Investor Day and Details Strategic Roadmap for Durable Growth
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Positive)
Tags
Key Terms
compound annual growth ratefinancial
The compound annual growth rate (CAGR) shows how much an investment or value has grown, on average, each year over a specific period. It considers the effect of growth that compounds or builds upon itself, similar to how interest accumulates in a savings account. Investors use CAGR to compare different investments’ long-term performance and to understand how steady or consistent their growth has been over time.
CAGRfinancial
Compound Annual Growth Rate (CAGR) measures the average yearly growth of an investment, revenue, or other metric over a multi-year period as if it had grown at a steady rate each year. Think of it like the constant speed that would take you from the starting value to the ending value over the same time—useful because it smooths out ups and downs and lets investors compare different assets or performance periods on an even footing.
operating marginfinancial
Operating margin shows how much profit a company makes from its core business activities after paying for costs like wages and materials. It’s useful because it tells you how efficiently a company is running—higher margins mean it keeps more money from each dollar of sales, which can indicate better management or stronger products.
adjusted earnings per sharefinancial
Adjusted Earnings Per Share shows how much profit a company makes for each share of stock, but it removes unusual or one-time items like big expenses or gains. This helps investors see the company's true ongoing performance, making it easier to compare how well different companies are doing over time.
non-GAAPfinancial
Non-GAAP refers to financial measures that companies use to show their earnings or performance without including certain expenses or income that are often added back to give a different picture. It matters because it can make a company's results look better or more favorable, but it may also hide important costs, so investors need to look at both GAAP (official rules) and non-GAAP numbers to get a full understanding.
Announces Long-Range Targets Including 7% - 10% Revenue CAGR Through 2028
Highlights Clear Focus on Patient Outcomes, Technology Innovation and Commercial Execution
IRVINE, Calif.--(BUSINESS WIRE)--
Masimo (NASDAQ: MASI) today hosted its 2025 Investor Day at the Company’s headquarters. At the event, Masimo’s management team provided an update on the Company’s long-term strategy, including the pathway for expanding Masimo’s position as a global leader in patient monitoring, the Company’s multi-year pipeline, and a clear roadmap to deliver durable revenue growth, margin expansion and increased cash flow. Masimo also provided a detailed look at each of its growth pillars.
The Company’s updated long-range plan through 2028 includes the following financial targets:
Revenue: Compound annual growth rate (CAGR) of 7%-10%
Operating Margin: Approximately 30% by 2028
Adjusted Earnings Per Share: $8.00 by 2028
Operating Cash Flow: Approximately $1 billion cumulatively from 2026-2028
Masimo also reaffirmed the 2025 financial guidance it last stated on November 4, including Non-GAAP Revenue of $1,510 - $1,530 million, Non-GAAP operating profit of $412 - $424 million and Non-GAAP earnings per diluted share of $5.40 - $5.55.
“Masimo’s market leading position is driven by our mission to deliver innovations that empower clinicians and transform patient care,” said Katie Szyman, Chief Executive Officer of Masimo. “As we enter this next chapter, we are incredibly well positioned to advance that mission. We have the team, the innovation engine and the clear execution plan to continue building on this success and unlock Masimo’s full potential. Our commitment is to deliver long-term value to patients, shareholders, employees and partners.”
Webcast of Masimo Investor Day
A replay of the webcast can be accessed through the link below:
Masimo Investor Day Webcast
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Masimo innovations empower clinicians to transform patient care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies, which can be found at www.masimo.com/evidence/featured-studies/feature. Masimo SET® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2025 Newsweek World’s Best Hospitals listing. Additional information about Masimo and its products may be found at www.masimo.com.
